Travere Therapeutics (NASDAQ:TVTX – Get Free Report) announced its earnings results on Thursday. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.01, Briefing.com reports. Travere Therapeutics had a negative return on equity of 269.18% and a negative net margin of 82.14%. The firm had revenue of $62.90 million during the quarter, compared to the consensus estimate of $60.87 million. During the same quarter in the prior year, the company earned ($1.17) EPS. The firm’s revenue for the quarter was up 69.6% compared to the same quarter last year.
Travere Therapeutics Trading Down 1.4 %
NASDAQ TVTX traded down $0.25 on Thursday, reaching $17.50. The company had a trading volume of 1,465,143 shares, compared to its average volume of 1,396,398. The stock’s 50 day moving average is $14.18 and its 200-day moving average is $9.96. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -9.44 and a beta of 0.73. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a 52 week low of $5.12 and a 52 week high of $19.25.
Insider Activity at Travere Therapeutics
In other Travere Therapeutics news, Director Jeffrey A. Meckler sold 40,000 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $14.06, for a total value of $562,400.00. Following the completion of the transaction, the director now directly owns 81,000 shares of the company’s stock, valued at approximately $1,138,860. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Eric M. Dube sold 21,125 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.52, for a total transaction of $243,360.00. Following the completion of the transaction, the chief executive officer now directly owns 361,975 shares of the company’s stock, valued at approximately $4,169,952. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey A. Meckler sold 40,000 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $14.06, for a total value of $562,400.00. Following the transaction, the director now directly owns 81,000 shares of the company’s stock, valued at $1,138,860. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 110,707 shares of company stock worth $1,504,312. 4.06% of the stock is owned by insiders.
Wall Street Analyst Weigh In
View Our Latest Report on Travere Therapeutics
About Travere Therapeutics
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
See Also
- Five stocks we like better than Travere Therapeutics
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- The Role Economic Reports Play in a Successful Investment Strategy
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- What does consumer price index measure?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.